Cassava’s humble appearance ... Searching the landscape for food burns calories, the very resource being sought. This paradox forced a trade-off for the hunter-gatherers: burn calories searching for ...

Start TODAY’s October 2024 walking challenge is all about turning your walk into a HIIT workout so TODAY fitness contributor Stephanie Mansour shares how you can lose the same amount of calories in ...

An upright, branching evergreen shrub to 2.5m high, with trunk-like stems and terminal rosettes of lance-shaped, stiff, arching to recurved leaves. Leaves are up to 90cm long, and blue-green when ...

eventually forms a tall, sparsely-branched evergreen tree but is usually seen in cultivation with a single, short trunk. The stiff, spine-tipped leaves, up to 50cm long, have peeling, thread-like ...

Cassava Sciences and two former executives agreed to pay more than $40 million in a settlement with the SEC. The SEC said that Cassava made misleading statements about a clinical trial of its ...

Although Nigeria is ranked number one in cassava production globally, she imported about $54,200 in cassava in 2022, becoming the 121st largest importer of cassava in the world. This was disclosed ...

Investors with a lot of money to spend have taken a bearish stance on Cassava Sciences SAVA. And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Cassava Sciences (NASDAQ:SAVA) has agreed to pay $40M to settle charges by the U.S. Securities and Exchange Commission (SEC) that the drug developer made misleading claims about the 2020 trial ...

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made misleading statements about phase 2b data on its Alzheimer’s disease drug candidate. The U.S ...

Cassava Sciences and its executives agreed to pay $40 million in penalties for misleading investors. Dr. Wang, a consultant, manipulated clinical trial data, leading to misleading Alzheimer's ...

Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns have agreed to pay over $40 million to resolve SEC ...